publications-2011-2013

CD49d expression as a promising biomarker to monitor natalizumab efficacy

Published on 19 March 2015

CD49d expression as a promising biomarker to monitor natalizumab efficacy
Authors	Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, Le Mauff B
Journal	JOURNAL OF THE NEUROLOGICAL SCIENCES 314 (1-2), 138-142, 2012
Year	2012
Institute	I2BM

Retour à la liste

Top page

Alternative and Atomic Energies Agency

CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.

The Knowledge Factory

In the same section :

CD49d expression as a promising biomarker to monitor natalizumab efficacy

Browse the site

Alternative and Atomic Energies Agency

Browse the portal

The Knowledge Factory

About Fundamental Research Division

Research fields

Scientific results

In the same section :

CD49d expression as a promising biomarker to monitor natalizumab efficacy

Browse the site

Alternative and Atomic Energies Agency

Browse the portal